First Results from the TERAVOLT Registry: mortality among thoracic cancer patients with COVID-19 is unexpectedly high
Mortality rates do not appear to be associated with any specific type of treatment or comorbidity in this patient group
Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
Mortality rates do not appear to be associated with any specific type of treatment or comorbidity in this patient group
It was developed as a biosimilar medicine
Treatment delay of at least 2 months reported in only one quarter of patients
Approval is based on the results from the E1912 trial
Efficacy in patients with metastatic triple negative breast cancer was demonstrated in IMMU-132-01 study
An experience in New York City
Evidence for efficacy is based on the results from the HER2CLIMB trial
FDA also approved a companion diagnostic for patient selection
It is approved for patients who have symptomatic, inoperable plexiform neurofibromas
With Massimo Di Maio, Mauriziano Hospital, Turin, Italy
Research priorities related to incidence, morbidity and mortality of COVID-19 specific to patients with cancer
Efficacy of mitomycin for pyelocaliceal use is determined in an ongoing OLYMPUS trial
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.